Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 15;83(2):156–163. doi: 10.1054/bjoc.2000.1200

Osteopontin is required for full expression of the transformed phenotype by the ras oncogene

Y Wu 1, D T Denhardt 1, S R Rittling 1
PMCID: PMC2363489  PMID: 10901364

Abstract

The secreted phosphoprotein osteopontin (OPN) is strongly associated with the process of neoplastic transformation, based both on its pattern of expression in vivo and in vitro and on functional analyses. We have used 3T3 cells derived from wildtype and OPN-deficient mice and transformed by transfection with oncogenic ras to assess the role of OPN in transformation in vitro and in tumorigenesis in vivo. There was no effect of an absence of OPN on the ability of the cells to undergo immortalization or to form morphologically transformed foci following ras transfection. Wildtype and OPN-deficient cell lines were established from such foci, and lines with similar ras mRNA levels selected for further analysis. Ras -transformed cell lines from both wildtype and OPN-deficient mice could form colonies in soft agar indicating that this process can occur in the absence of OPN. However, the ability of the OPN-deficient cell lines to form colonies was reduced as compared to wildtype cell lines. Tumorigenesis in syngeneic and nude mice was assessed for a subset of cell lines that formed colonies efficiently in soft agar. Cell lines unable to make OPN formed tumors in these mice much more slowly than wildtype cells, despite similar growth of the cells on plastic and in soft agar. Taken together, these results indicate that maximal transformation by ras requires OPN expression, and implicate increased OPN expression as an important effector of the transforming activity of the ras oncogene. © 2000 Cancer Research Campaign

Keywords: tumorigenesis, anchorage-independence, ras, integrins, immortalization

Full Text

The Full Text of this article is available as a PDF (312.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayless K. J., Meininger G. A., Scholtz J. M., Davis G. E. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci. 1998 May;111(Pt 9):1165–1174. doi: 10.1242/jcs.111.9.1165. [DOI] [PubMed] [Google Scholar]
  2. Behrend E. I., Craig A. M., Wilson S. M., Denhardt D. T., Chambers A. F. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 1994 Feb 1;54(3):832–837. [PubMed] [Google Scholar]
  3. Bellahcène A., Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995 Jan;146(1):95–100. [PMC free article] [PubMed] [Google Scholar]
  4. Brooks P. C., Clark R. A., Cheresh D. A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994 Apr 22;264(5158):569–571. doi: 10.1126/science.7512751. [DOI] [PubMed] [Google Scholar]
  5. Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 Dec 30;79(7):1157–1164. doi: 10.1016/0092-8674(94)90007-8. [DOI] [PubMed] [Google Scholar]
  6. Brown L. F., Papadopoulos-Sergiou A., Berse B., Manseau E. J., Tognazzi K., Perruzzi C. A., Dvorak H. F., Senger D. R. Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994 Sep;145(3):610–623. [PMC free article] [PubMed] [Google Scholar]
  7. Casson A. G., Wilson S. M., McCart J. A., O'Malley F. P., Ozcelik H., Tsao M. S., Chambers A. F. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer. 1997 Sep 4;72(5):739–745. doi: 10.1002/(sici)1097-0215(19970904)72:5<739::aid-ijc6>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  8. Chambers A. F., Behrend E. I., Wilson S. M., Denhardt D. T. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res. 1992 Jan-Feb;12(1):43–47. [PubMed] [Google Scholar]
  9. Chambers A. F., Colella R., Denhardt D. T., Wilson S. M. Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinog. 1992;5(3):238–245. doi: 10.1002/mc.2940050311. [DOI] [PubMed] [Google Scholar]
  10. Chambers A. F., Denhardt G. H., Wilson S. M. ras-transformed NIH 3T3 cell lines, selected for metastatic ability in chick embryos, have increased proportions of p21-expressing cells and are metastatic in nude mice. Invasion Metastasis. 1990;10(4):225–240. [PubMed] [Google Scholar]
  11. Chambers A. F., Hota C., Prince C. W. Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin. Cancer Res. 1993 Feb 1;53(3):701–706. [PubMed] [Google Scholar]
  12. Chen H., Ke Y., Oates A. J., Barraclough R., Rudland P. S. Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene. 1997 Apr 3;14(13):1581–1588. doi: 10.1038/sj.onc.1200993. [DOI] [PubMed] [Google Scholar]
  13. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci. 1998 Jun;54(6):541–548. doi: 10.1007/s000180050182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Craig A. M., Bowden G. T., Chambers A. F., Spearman M. A., Greenberg A. H., Wright J. A., McLeod M., Denhardt D. T. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer. 1990 Jul 15;46(1):133–137. doi: 10.1002/ijc.2910460124. [DOI] [PubMed] [Google Scholar]
  15. Crawford H. C., Matrisian L. M., Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 1998 Nov 15;58(22):5206–5215. [PubMed] [Google Scholar]
  16. Denda S., Reichardt L. F., Müller U. Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol Biol Cell. 1998 Jun;9(6):1425–1435. doi: 10.1091/mbc.9.6.1425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Denhardt D. T., Chambers A. F. Overcoming obstacles to metastasis--defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem. 1994 Sep;56(1):48–51. doi: 10.1002/jcb.240560109. [DOI] [PubMed] [Google Scholar]
  18. Feng B., Rollo E. E., Denhardt D. T. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin Exp Metastasis. 1995 Nov;13(6):453–462. doi: 10.1007/BF00118184. [DOI] [PubMed] [Google Scholar]
  19. Freedman V. H., Shin S. I. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell. 1974 Dec;3(4):355–359. doi: 10.1016/0092-8674(74)90050-6. [DOI] [PubMed] [Google Scholar]
  20. Frisch S. M., Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 1997 Oct;9(5):701–706. doi: 10.1016/s0955-0674(97)80124-x. [DOI] [PubMed] [Google Scholar]
  21. Gardner H. A., Berse B., Senger D. R. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene. 1994 Aug;9(8):2321–2326. [PubMed] [Google Scholar]
  22. Giachelli C. M., Lombardi D., Johnson R. J., Murry C. E., Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998 Feb;152(2):353–358. [PMC free article] [PubMed] [Google Scholar]
  23. Goligorsky M. S., Noiri E., Kessler H., Romanov V. Therapeutic potential of RGD peptides in acute renal injury. Kidney Int. 1997 May;51(5):1487–1492. doi: 10.1038/ki.1997.204. [DOI] [PubMed] [Google Scholar]
  24. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547–5551. doi: 10.1073/pnas.89.12.5547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Guo X., Zhang Y. P., Mitchell D. A., Denhardt D. T., Chambers A. F. Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol. 1995 Jan;15(1):476–487. doi: 10.1128/mcb.15.1.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hirota S., Ito A., Nagoshi J., Takeda M., Kurata A., Takatsuka Y., Kohri K., Nomura S., Kitamura Y. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest. 1995 Jan;72(1):64–69. [PubMed] [Google Scholar]
  27. Hu D. D., Hoyer J. R., Smith J. W. Ca2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin alpha v beta 3. J Biol Chem. 1995 Apr 28;270(17):9917–9925. doi: 10.1074/jbc.270.17.9917. [DOI] [PubMed] [Google Scholar]
  28. Hu D. D., Lin E. C., Kovach N. L., Hoyer J. R., Smith J. W. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem. 1995 Nov 3;270(44):26232–26238. doi: 10.1074/jbc.270.44.26232. [DOI] [PubMed] [Google Scholar]
  29. Hwang S. M., Lopez C. A., Heck D. E., Gardner C. R., Laskin D. L., Laskin J. D., Denhardt D. T. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem. 1994 Jan 7;269(1):711–715. [PubMed] [Google Scholar]
  30. Hynes R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992 Apr 3;69(1):11–25. doi: 10.1016/0092-8674(92)90115-s. [DOI] [PubMed] [Google Scholar]
  31. Juliano R. Signal transduction by integrins and its role in the regulation of tumor growth. Cancer Metastasis Rev. 1994 Mar;13(1):25–30. doi: 10.1007/BF00690416. [DOI] [PubMed] [Google Scholar]
  32. Katagiri Y. U., Sleeman J., Fujii H., Herrlich P., Hotta H., Tanaka K., Chikuma S., Yagita H., Okumura K., Murakami M. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 1999 Jan 1;59(1):219–226. [PubMed] [Google Scholar]
  33. Liaw L., Birk D. E., Ballas C. B., Whitsitt J. S., Davidson J. M., Hogan B. L. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998 Apr 1;101(7):1468–1478. doi: 10.1172/JCI1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Liaw L., Skinner M. P., Raines E. W., Ross R., Cheresh D. A., Schwartz S. M., Giachelli C. M. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995 Feb;95(2):713–724. doi: 10.1172/JCI117718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Malyankar U. M., Rittling S. R., Connor A., Denhardt D. T. The mitogen-regulated protein/proliferin transcript is degraded in primary mouse embryo fibroblast but not 3T3 nuclei: altered RNA processing correlates with immortalization. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):335–339. doi: 10.1073/pnas.91.1.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Montgomery A. M., Reisfeld R. A., Cheresh D. A. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8856–8860. doi: 10.1073/pnas.91.19.8856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Noiri E., Dickman K., Miller F., Romanov G., Romanov V. I., Shaw R., Chambers A. F., Rittling S. R., Denhardt D. T., Goligorsky M. S. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int. 1999 Jul;56(1):74–82. doi: 10.1046/j.1523-1755.1999.00526.x. [DOI] [PubMed] [Google Scholar]
  38. Oates A. J., Barraclough R., Rudland P. S. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene. 1996 Jul 4;13(1):97–104. [PubMed] [Google Scholar]
  39. Renshaw M. W., Ren X. D., Schwartz M. A. Growth factor activation of MAP kinase requires cell adhesion. EMBO J. 1997 Sep 15;16(18):5592–5599. doi: 10.1093/emboj/16.18.5592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Rittling S. R. Clonal nature of spontaneously immortalized 3T3 cells. Exp Cell Res. 1996 Nov 25;229(1):7–13. doi: 10.1006/excr.1996.0337. [DOI] [PubMed] [Google Scholar]
  41. Rittling S. R., Denhardt D. T. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol. 1999 Mar-Apr;7(2):103–113. doi: 10.1159/000020591. [DOI] [PubMed] [Google Scholar]
  42. Rittling S. R., Feng F. Detection of mouse osteopontin by western blotting. Biochem Biophys Res Commun. 1998 Sep 18;250(2):287–292. doi: 10.1006/bbrc.1998.9306. [DOI] [PubMed] [Google Scholar]
  43. Rittling S. R., Matsumoto H. N., McKee M. D., Nanci A., An X. R., Novick K. E., Kowalski A. J., Noda M., Denhardt D. T. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res. 1998 Jul;13(7):1101–1111. doi: 10.1359/jbmr.1998.13.7.1101. [DOI] [PubMed] [Google Scholar]
  44. Rittling S. R., Novick K. E. Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ. 1997 Oct;8(10):1061–1069. [PubMed] [Google Scholar]
  45. Rollo E. E., Laskin D. L., Denhardt D. T. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J Leukoc Biol. 1996 Sep;60(3):397–404. doi: 10.1002/jlb.60.3.397. [DOI] [PubMed] [Google Scholar]
  46. Ruoslahti E. Integrins as signaling molecules and targets for tumor therapy. Kidney Int. 1997 May;51(5):1413–1417. doi: 10.1038/ki.1997.193. [DOI] [PubMed] [Google Scholar]
  47. Scatena M., Almeida M., Chaisson M. L., Fausto N., Nicosia R. F., Giachelli C. M. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol. 1998 May 18;141(4):1083–1093. doi: 10.1083/jcb.141.4.1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Schwartz M. A. Integrins, oncogenes, and anchorage independence. J Cell Biol. 1997 Nov 3;139(3):575–578. doi: 10.1083/jcb.139.3.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Senger D. R., Asch B. B., Smith B. D., Perruzzi C. A., Dvorak H. F. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983 Apr 21;302(5910):714–715. doi: 10.1038/302714a0. [DOI] [PubMed] [Google Scholar]
  50. Senger D. R., Ledbetter S. R., Claffey K. P., Papadopoulos-Sergiou A., Peruzzi C. A., Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol. 1996 Jul;149(1):293–305. [PMC free article] [PubMed] [Google Scholar]
  51. Senger D. R., Perruzzi C. A., Gracey C. F., Papadopoulos A., Tenen D. G. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 1988 Oct 15;48(20):5770–5774. [PubMed] [Google Scholar]
  52. Senger D. R., Perruzzi C. A., Papadopoulos-Sergiou A., Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell. 1994 May;5(5):565–574. doi: 10.1091/mbc.5.5.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Singh R. P., Patarca R., Schwartz J., Singh P., Cantor H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med. 1990 Jun 1;171(6):1931–1942. doi: 10.1084/jem.171.6.1931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Smith L. L., Cheung H. K., Ling L. E., Chen J., Sheppard D., Pytela R., Giachelli C. M. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem. 1996 Nov 8;271(45):28485–28491. [PubMed] [Google Scholar]
  55. Somerman M. J., Prince C. W., Butler W. T., Foster R. A., Moehring J. M., Sauk J. J. Cell attachment activity of the 44 kilodalton bone phosphoprotein is not restricted to bone cells. Matrix. 1989 Jan;9(1):49–54. doi: 10.1016/s0934-8832(89)80018-6. [DOI] [PubMed] [Google Scholar]
  56. Strömblad S., Becker J. C., Yebra M., Brooks P. C., Cheresh D. A. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest. 1996 Jul 15;98(2):426–433. doi: 10.1172/JCI118808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Su L., Mukherjee A. B., Mukherjee B. B. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene. 1995 Jun 1;10(11):2163–2169. [PubMed] [Google Scholar]
  58. Tuck A. B., O'Malley F. P., Singhal H., Harris J. F., Tonkin K. S., Kerkvliet N., Saad Z., Doig G. S., Chambers A. F. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998 Oct 23;79(5):502–508. doi: 10.1002/(sici)1097-0215(19981023)79:5<502::aid-ijc10>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  59. Weber G. F., Ashkar S., Glimcher M. J., Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996 Jan 26;271(5248):509–512. doi: 10.1126/science.271.5248.509. [DOI] [PubMed] [Google Scholar]
  60. Zhang Z., Vuori K., Reed J. C., Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6161–6165. doi: 10.1073/pnas.92.13.6161. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES